EP3645015A1 - A composite mixture comprising cannabis sativa - Google Patents

A composite mixture comprising cannabis sativa

Info

Publication number
EP3645015A1
EP3645015A1 EP18746071.2A EP18746071A EP3645015A1 EP 3645015 A1 EP3645015 A1 EP 3645015A1 EP 18746071 A EP18746071 A EP 18746071A EP 3645015 A1 EP3645015 A1 EP 3645015A1
Authority
EP
European Patent Office
Prior art keywords
mixture
weight
treatment
composite mixture
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18746071.2A
Other languages
German (de)
French (fr)
Inventor
Frantisek Bednarik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3645015A1 publication Critical patent/EP3645015A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to a composite mixture for the treatment, or the treatment support of neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases using an extract from cannabis sativa plants and homogenized parts thereof.
  • the disturbed homeostasis is signaled, inter alia, by entire groups of diagnoses, which often intermingle with each other and show up with protracted, often chronic, inflammations and metabolic disorders, such as various eczema, muscle and joint pain, fatigue, digestive problems (colitis, obstipation), vascular diseases, poor metabolism of some parts of food intake (carbohydrates - pancreas, lipids - gallbladder, . . .).
  • Some of these diseases, such as chronic constipation can produce, due to a very long digestion process, biochemicals of a toxic nature and neurotoxins, causing both mutagenic changes in cells in the organism (leading to the formation of cancer cells), and significant reduction in immunity of the organism.
  • probiotics are administered, which are generally in principle based on the delivery of microorganism preparations of lactic fermentation (Lactobacillus ssp.).
  • the composite mixture according to the invention which consists in that the mixture for the treatment, or the treatment support of neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases comprises from 0.1 to 25.0 % by weight of extract from cannabis sativa plant or its homogenized parts, and from 0.1 to 25.0 % by weight of extract of selected types of medicinal plants or homogenized parts thereof, and from 0.1 to 50.0 % by weight of insoluble fibers, and from 0.3 to 99.7% by weight of a mixture of vegetable oils.
  • the technical solution is also new in that the composite mixture is intended for oral administration in human and/or veterinary medicine for the treatment, or the treatment support of stated neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases.
  • a composite mixture for the treatment of intestinal microflora e.g. after treatment with antibiotics or after chemotherapy.
  • This mixture can also be used in auxiliary treatment of e.g. ulcerative colitis and other inflammatory diseases of the digestive tract, especially the small intestine and large intestine.
  • the mixture contains: a mixture of vegetable oils (rapeseed, hemp, linseed) 60% insoluble fibers 30% a mixture of cannabinoids (CBD, CBG, ...) 1% a mixture of herbs and extracts of selected medicinal plants
  • a composite mixture for the treatment of metabolic problems of the pancreas is provided.
  • the mixture contains: a mixture of vegetable oils (rapeseed, hemp, linseed) 60% insoluble fibers 30% a mixture of cannabinoids 1% a mixture of herbs and extracts of selected medicinal plants
  • a composite mixture for the treatment of metabolism and for the regeneration of the liver can be used in hepatic impairment, as hepatoprotective, e.g. after chemotherapy.
  • the mixture contains: a mixture of vegetable oils (rapeseed, hemp, linseed) 60% insoluble fibers 30% a mixture of cannabinoids 1% a mixture of herbs and extracts of selected medicinal plants
  • the mixture contains: a mixture of vegetable oils (rapeseed, hemp, linseed) 60% insoluble fibers 30% a mixture of cannabinoids 1 % a mixture of herbs and extracts of selected medicinal plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)

Abstract

A composite mixture for the treatment or the treatment support of neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases wherein it comprises from 0.1 to 25% by weight of extract from cannabis sativa plant and/or its homogenized parts, and from 0.1 to 25% by weight of extract of selected types of medicinal plants and/or homogenized parts thereof, and from 0.1 to 50% by weight of insoluble fibers, and from 0.3 to 99.7% by weight of a mixture of vegetable oils.

Description

A COMPOSITE MIXTURE COMPRISING CANNABIS SATIVA
Field of the invention
The present invention relates to a composite mixture for the treatment, or the treatment support of neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases using an extract from cannabis sativa plants and homogenized parts thereof.
Background of the invention
An extensive spectrum of organism diseases is the result of a homeostasis disorder, i.e. the auto- regulatory mechanism, whose task is to maintain the individual parts of the living organism in the functional parameters and intervals, so as all vital functions necessary for its existence have been preserved. Unbalancing this dynamic equilibrium out of the functional intervals is manifested by the loss of self-regulation ability of the whole organism, and the symptom is the emergence of diseases. The disturbed homeostasis is signaled, inter alia, by entire groups of diagnoses, which often intermingle with each other and show up with protracted, often chronic, inflammations and metabolic disorders, such as various eczema, muscle and joint pain, fatigue, digestive problems (colitis, obstipation), vascular diseases, poor metabolism of some parts of food intake (carbohydrates - pancreas, lipids - gallbladder, . . .). Some of these diseases, such as chronic constipation, can produce, due to a very long digestion process, biochemicals of a toxic nature and neurotoxins, causing both mutagenic changes in cells in the organism (leading to the formation of cancer cells), and significant reduction in immunity of the organism. For immunity enhancement and as a support for the treatment of impaired immunity (e.g. for restoration and development of intestinal microflora after antibiotic treatment, after chemotherapeutic treatment of malignant tumors, etc.) probiotics are administered, which are generally in principle based on the delivery of microorganism preparations of lactic fermentation (Lactobacillus ssp.).
Detailed description of the invention
Problems of the state of the art are largely eliminated by the composite mixture according to the invention, which consists in that the mixture for the treatment, or the treatment support of neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases comprises from 0.1 to 25.0 % by weight of extract from cannabis sativa plant or its homogenized parts, and from 0.1 to 25.0 % by weight of extract of selected types of medicinal plants or homogenized parts thereof, and from 0.1 to 50.0 % by weight of insoluble fibers, and from 0.3 to 99.7% by weight of a mixture of vegetable oils. The technical solution is also new in that the composite mixture is intended for oral administration in human and/or veterinary medicine for the treatment, or the treatment support of stated neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases.
Working examples of the invention
Exemplary embodiments of the composite mixture according to the invention are the following: Example 1
A composite mixture for the treatment of intestinal microflora, e.g. after treatment with antibiotics or after chemotherapy. This mixture can also be used in auxiliary treatment of e.g. ulcerative colitis and other inflammatory diseases of the digestive tract, especially the small intestine and large intestine.
The mixture contains: a mixture of vegetable oils (rapeseed, hemp, linseed) 60% insoluble fibers 30% a mixture of cannabinoids (CBD, CBG, ...) 1% a mixture of herbs and extracts of selected medicinal plants
(walnut leaf 50%, raspberry leaf 50%) 9%
Example 2
A composite mixture for the treatment of metabolic problems of the pancreas.
This mixture can be used for the pancreatic impairment and DM type 2.
The mixture contains: a mixture of vegetable oils (rapeseed, hemp, linseed) 60% insoluble fibers 30% a mixture of cannabinoids 1% a mixture of herbs and extracts of selected medicinal plants
(mistletoe 30%, mulberry leaf 70%) 9% Example 3
A composite mixture for the treatment of metabolism and for the regeneration of the liver. This mixture can be used in hepatic impairment, as hepatoprotective, e.g. after chemotherapy.
The mixture contains: a mixture of vegetable oils (rapeseed, hemp, linseed) 60% insoluble fibers 30% a mixture of cannabinoids 1% a mixture of herbs and extracts of selected medicinal plants
(mistletoe 60%, centaury tops 20%, sage 20%) 9%
Example 4
A composite mixture for strengthening and maintaining the elasticity of the vascular walls.
This mixture can be used for inflammation of blood vessels and veins.
The mixture contains: a mixture of vegetable oils (rapeseed, hemp, linseed) 60% insoluble fibers 30% a mixture of cannabinoids 1 % a mixture of herbs and extracts of selected medicinal plants
(rutin 10%, black currant leaf 90%) 9%

Claims

1. A composite mixture for the treatment or the treatment support of neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases characterized in that it comprises from 0.1 to 25% by weight of extract from cannabis sativa plant and/or its homogenized parts, and from 0.1 to 25% by weight of extract of selected types of medicinal plants and/or homogenized parts thereof, and from 0.1 to 50% by weight of insoluble fibers, and from 0.3 to 99.7% by weight of a mixture of vegetable oils.
2. The composite mixture according to claim 1, characterized in that it is intended for oral administration in human and/or veterinary medicine for the treatment, or the treatment support of stated neurodegenerative, vascular, inflammatory, metabolic, and immunological diseases.
EP18746071.2A 2017-06-16 2018-06-15 A composite mixture comprising cannabis sativa Withdrawn EP3645015A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2017344 2017-06-16
PCT/CZ2018/000029 WO2018228616A1 (en) 2017-06-16 2018-06-15 A composite mixture comprising cannabis sativa

Publications (1)

Publication Number Publication Date
EP3645015A1 true EP3645015A1 (en) 2020-05-06

Family

ID=63035806

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18746071.2A Withdrawn EP3645015A1 (en) 2017-06-16 2018-06-15 A composite mixture comprising cannabis sativa

Country Status (3)

Country Link
EP (1) EP3645015A1 (en)
CA (1) CA3067436A1 (en)
WO (1) WO2018228616A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102448514B1 (en) * 2019-12-10 2022-10-05 한국 한의학 연구원 Composition for preventing, ameliorating or treating arteriosclerosis containing Cannabis sativa stem extract as effective component

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175259A1 (en) * 2017-03-18 2018-09-27 Mcgarrah Steven M Pet food including cannabidiolic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350251B2 (en) * 2012-03-28 2019-07-16 Keith Gerald Freeman Medical compositions, methods of making and using those compositions, and kits including those compositions
MX395015B (en) * 2014-12-12 2025-03-24 Ojai Energetics Pbc MICROENCAPSULATED COMPOSITIONS OF CANNABINOIDS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175259A1 (en) * 2017-03-18 2018-09-27 Mcgarrah Steven M Pet food including cannabidiolic acid

Also Published As

Publication number Publication date
WO2018228616A1 (en) 2018-12-20
CA3067436A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
Lan et al. Seabuckthorn polysaccharide ameliorates high-fat diet-induced obesity by gut microbiota-SCFAs-liver axis
Zhang et al. Bioavailability based on the gut microbiota: a new perspective
Yu et al. Isolation and biological properties of polysaccharide CPS-1 from cultured Cordyceps militaris
Garcia-Muñoz et al. Metabolic fate of ellagitannins: implications for health, and research perspectives for innovative functional foods
Mao et al. Anti-tumor and immunomodulatory activity of selenium (Se)-polysaccharide from Se-enriched Grifola frondosa
Shen et al. Polysaccharide from wheat bran induces cytokine expression via the toll-like receptor 4-mediated p38 MAPK signaling pathway and prevents cyclophosphamide-induced immunosuppression in mice
Xu et al. The contribution of side chains to antitumor activity of a polysaccharide from Codonopsis pilosula
Chen et al. Dietary proanthocyanidins on gastrointestinal health and the interactions with gut microbiota
KR101826673B1 (en) Composition for improving intestinal health containing Codonopsis lanceolata
Huang et al. Amelioration of obesity and inflammation by polysaccharide from unripe fruits of raspberry via gut microbiota regulation
Tian et al. Simulated digestion and fecal fermentation behaviors of exopolysaccharides from Paecilomyces cicadae TJJ1213 and its effects on human gut microbiota
Marcial et al. Effects of polysaccharide isolated from Streptococcus thermophilus CRL1190 on human gastric epithelial cells
CN107137628B (en) Hyaluronidase inhibitor derived from symbiotic fermentation product and application thereof
US9717766B2 (en) Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
Liu et al. Electrospray alginate microgels co-encapsulating degraded Konjac glucomannan and quercetin modulate human gut microbiota in vitro
Kakar et al. A review on extraction, composition, structure, and biological activities of polysaccharides from different parts of Nelumbo nucifera
Taherkhani et al. Flavonoids and the gut microbiome: a powerful duo for brain health
KR20180016875A (en) Composition for improving intestinal health comprising red yeast rice
Li et al. The potential role of alfalfa polysaccharides and their sulphated derivatives in the alleviation of obesity
Zhao et al. Polysaccharides from Pogostemon cablin (Blanco) Benth.: Characterization and antioxidant activities
EP3645015A1 (en) A composite mixture comprising cannabis sativa
CN113693237A (en) Novel natural solid intervention agent for intervening lactose intolerance diarrhea, preparation method and application
CN112915208A (en) Composition with function of perfecting diversity of personalized intestinal flora and application thereof
CN110859871A (en) Composition for treating prostatitis and preparation method thereof
CN103599214B (en) A kind of probiotics fermentation-type embolism extinguishing oral liquid and preparation method thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230620